Cat. No.
MABL-3673
Application
therapeutic, Block, FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
MLN1202 (Plozalizumab, hu1D9)
From
Recombinant Antibody
Specificity
This antibody binds and epitope between amino acids 1-30 in the amino terminal region of human CC-chemokine receptor 2. CCR2 receptor is a key functional receptor for CCL2, a chemokine which specifically mediates monocyte chemotaxis. CCL2 is involved in monocyte infiltration in inflammatory diseases such as rheumatoid arthritis as well as in the inflammatory response against tumors. It can also bind CCL7 and CCL12. It further regulates the expression of T-cell inflammatory cytokines and T-cell differentiation, promoting the differentiation of T-cells into T-helper 17 cells (Th17) during inflammation.
Alternative Names
CD192; C-C chemokine receptor type 2; C-C CKR-2; CC-CKR-2; CCR-2; Monocyte chemoattractant protein 1 receptor; MCP-1-R; CMKBR2; MLN-1202; 4.9.2; LS132.1D9
UniProt
P41597
Immunogen
The parental mouse antibody 1D9 was generated by immunizing mice with L1.2 transfectants expressing CCR2. The original humanized version of the antibody was generated by grafting CDRs of the mouse antibody 1D9 onto human framework regions.
Application Notes
The binding characterization of the original mouse parental antibody 1D9 for human CCR2 was done using flow cytometry. This humanized antibody was capable of inhibit the binding of [125I]- MCP-1 to whole THP-1 cells (US6696550). In a clinical trial study, in patients with active rheumatoid arthritis (RA), it was reported that treatment with anti-CCR2 blocking antibody did not result in amelioration of synovial inflammation in active RA (PMID: 18576354). In a study in patients with risk factors for atherosclerotic cardiovascular disease (ASCVD), it was reported that that blockade of CCR2 with MLN1202 reduces C-reactive protein, a biomarker related to inflammation in patients at risk for ASCVD (Davidson et. al., 2007). In another study, patients with ASCVD, who received MLN1202 exhibited significant decreases in high-sensitivity C-reactive protein levels, beginning at 4 weeks and continuing through 12 weeks after dosing (PMID: 21247529).
Antibody First Published
Vergunst et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2008 Jul;58(7):1931-9 PMID:18576354
Note on publication
This study examines the effect of CCR2 blockade on synovial inflammation in rheumatoid arthritis.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
